Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
39 Items
Title  Creator  Group name  Publishing year 
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer Rabia et al. EquipeJC 2023
Carcinoembryonic Antigen - Related Cell Adhesion Molecule Type 5 Receptor - Targeted Fluorescent Intraoperative Molecular Imaging Tracer for Lung Cancer: A Nonrandomized Controlled Trial Azari et al. EquipeAP 2023-01-27
Proof of concept of improved fluorescence-guided surgery of colon cancer liver metastasis using color-coded imaging of a tumor-labeling fluorescent antibody and indocyanine green restricted to the adjacent liver segment Nishino et al. EquipeAP 2022-08-01
Improving Patients' Life Quality after Radiotherapy Treatment by Predicting Late Toxicities Lapierre et al. EquipeJPP 2022-04-22
Glycoprotein Receptor CEACAM5-Targeted Intraoperative Molecular Imaging Tracer in Non-Small Cell Lung Cancer Azari et al. EquipeAP 5/2022
Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures Larbouret et al. EquipeELC 2021-09-15
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models Rabia et al. EquipeCG 2021 Jan-Dec
Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival Chauvin et al. EquipeCG 2021-07
Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells Chauvin et al. EquipeCTCS 2021-01-26
Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells Bourillon et al. EquipeAP Jan 17, 2020
Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody-dependent HER4 intracellular domain trafficking Lanotte et al. EquipePM Jul 2020
[Radioimmunotherapy: the reasons for confidential clinical use and hope for development] Barbet et al. EquipeAP Dec 2019
[Players from the program "Investments for the Future": MAbImprove MabEx] Larivière et al. EquipeAP Dec 2019
[Antibodies, tools of choice for fluorescence-guided surgery] Pèlegrin et al. EquipeAP Dec 2019
[A word from the coordinators] Pèlegrin et al. EquipeAP Dec 2019
Toxicity and pharmacokinetic profile of SGM-101, a fluorescent anti-CEA chimeric antibody for fluorescence imaging of tumors in patients Framery et al. EquipeAP 2019
Quantitative proteomic analysis reveals AK2 as potential biomarker for late normal tissue radiotoxicity Lacombe et al. EquipePC Aug 09, 2019
Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples Ho-Pun-Cheung et al. EquipeCTCS Dec 03, 2019
ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells Le Clorennec et al. EquipeAP Aug 23, 2019
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies Ashraf et al. EquipeAT Feb 04, 2019
An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer Bourillon et al. EquipeELC 2019-10-01
Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer Ogier et al. EquipeAP 09 28, 2018
Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study Boogerd et al. EquipeAP Mar 2018
Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent Hoogstins et al. EquipeAP Jul 26, 2018
Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France Martin et al. EquipeAP 2018 Feb/Mar
12>>>
39 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés